| Sumario: | Significance & Background: Cellular therapies are rapidly expanding as treatment options for patients with cancer and non-cancer diagnoses. Recent FDA approvals of cellular therapies for the treatment of solid tumor malignancies includes tumor-infiltrating lymphocytes (TILs) for metastatic melanoma. TIL therapy is associated with the risk of potential life-threatening reactions and therefore requires expert multidisciplinary teams to oversee the care of these patients. Purpose: The purpose of this project was to create a collaborative and comprehensive model of care, applying established cellular therapy operations and guidelines to the TIL patient. This model provides guidelines from referral to post infusion monitoring and establishes roles and responsibilities of the care team. Interventions: Cellular therapy and solid tumor stakeholders met frequently to establish standards of care, including toxicity management. An institutional Solid Tumor Immune Effector Cell (IEC) policy was established. A comprehensive flowchart was created to identify all points of care for a TIL patient. The cellular therapy coordinators partnered with the melanoma practice RN to incorporate this new patient population into their caseload to provide oversight of referral and planning processes. The workgroup determined that TILs patients would use existing inpatient and outpatient solid tumor services and treatment locations to expand institutional cellular therapy knowledge. Solid tumor nurses received training on TIL therapy, lymphodepletion regimens, and side effects. Hands-on training was completed for the infusion of the TIL product, with 1:1 resourcing on infusion days. Surgeons and surgical staff were engaged to establish procurement workflows. Patient education materials were developed. A solid tumor IEC consult service was created to provide 24/7 access for toxicity management. Results: Since December 2024, 15 patients have been referred for TIL therapy. Four patients were unable to proceed due to ineligibility. Seven patients received their TIL infusions after successfully completing lymphodepletion in the outpatient infusion clinic. Patients with planned admission for TIL infusion and IL-2 had a median length of stay of nine days and zero ICU admissions occurred in these patients. Discussion: The expansion of cellular therapy outside of the hematologic malignancy program requires a multidisciplinary team to establish practices that are aligned with other cellular therapy policies and ensure patient safety. This center has demonstrated that utilizing the combined expertise of existing cellular therapy groups with disease specialists can successfully expand cellular therapy operations for new indications into new areas.e
|
|---|